(Q36194596)

12 August 2017

1 reference

title

Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure (English)

1 reference

12 August 2017

1 reference

Lay-Cheng Lim

1

1 reference

12 August 2017

publication date

1 June 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

10

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

255-259

1 reference

Pure red-cell aplasia and epoetin therapy.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026154

Evaluation of clinical guidelines for the management of end-stage renal disease in europe: the EU BIOMED 1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026154

Anti-erythropoietin antibodies and pure red cell aplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026154

Antibodies against rHuEPO: native and recombinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026154

Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026154

Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026154

Recovery from pure red cell aplasia caused by anti-erythropoietin antibodies after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026154

Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026154

Bioequivalence and the immunogenicity of biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026154

Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026154

Expecting the unexpected--drug safety, pharmacovigilance, and the prepared mind.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026154

10.1080/10245330400026154

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference